Johnson and Johnson (JNJ) has lost 4 of the 6 ovarian cancer-related trials even though there is no scientific consensus regarding causation between talc powder and ovarian cancer. This, on the surface, appears very strange as plaintiffs should not be able to prove causation. Unfortunately for JNJ shareholders, the lack of scientific consensus has turned the lawsuit in a battle of credibility. Do jurors believe the sympathetic lady diagnosed with ovarian cancer? Or do jurors believe a multi-billion dollar corporation that has faced multiple scandals, already lost similar cases and is quoting from studies which it has financed? Clearly, it is the former. These law suits will continue to drag the stock down for a considerable time.

READ FULL ARTICLE HERE